In this study, we compared the clinical efficacy of JOINS (SKI306X, SK Chemicals) with placebo on cartilage protection using magnetic resonance imaging (MRI). Materials and Methods: Sixtynine patients were randomized to the JOINS group (200 mg, three times daily for 1 year; n=33) or the placebo group (n=36). Changes in cartilage volume and thickness were measured using MRI. Changes in the delayed gadoliniumenhanced MRI of cartilage (dGEMRIC) index, subchondral bone marrow abnormality scores, and clinical scores including knee pain visual analog scale (VAS) score and Korean Western Ontario and McMaster Universities Osteoarthritis Index (KWOMAC) were also evaluated. Results: Changes in cartilage thickness and volume and subarticular bone marrow abnormality scores were not different between groups. Changes in the dGEMRIC index in the lateral tibial plateau were greater in the JOINS group than in the placebo group (19.64±114.33 msec vs. -57.77±123.30 msec; p=0.011). Significantly greater changes in VAS were observed in the JOINS group than in the placebo group (-26 
Introduction
Knee osteoarthritis (OA) is one of the most common joint dis eases. The function of the articular cartilage is to facilitate move ment by providing a soft, smooth surface for the weight bearing portion of the joint, and to protect portions of the joint under concentrated load against damage. OA is a disease in which the joint cartilage playing these important roles wears down, and the underlying bone is also damaged, resulting in deformation as the bone regenerates and occurrence of a number of symptoms 14) . Conservative treatment options for OA consist of nonphar macological treatment, such as exercise, weight loss, and lifestyle education and pharmacological treatment using acetaminophen, nonsteroidal antiinflammatory drugs (NSAIDs), and analge sics 57) . Although NSAIDs and analgesics have established efficacy in knee OA, several adverse effects have been reported, such as gastrointestinal ulcer and hemorrhage and cardiovascular, he patic, and renal toxicity 811) . Glucosamine and chondroitin sulfate are widely used as a supplement for pain relief and cartilage pro tection, but their efficacy remains unclear 1215) . Herbal antiarthritic medicines have been widely used as a treatment for OA in Eastern countries. Although the mechanism of these treatments has not been fully evaluated, there are several studies demonstrating supportive evidence concerning their ef . JOINS tablet (SKI306X, SK Chemicals, Seongnam, Korea) is one of such herbal antiarthritic drugs. The tablet is made with powdered extract of herbs, Clematis mandshurica, Trichosanthes kirilowii, and Prunella vulgaris mixed at 1:2:1 weight ratio in an alcoholic aqueous solution, followed by frac tionating with watersaturated butanol and complete removal of residual solvents. In vitro studies showed that JOINS can inhibit the degradation of articular tissue caused by free radicals that are produced as a result of ischemic reperfusion associated with pres sure change in the articular cavity 2023) . This clinical study was designed to evaluate the effect of JOINS on cartilage protection using magnetic resonance imaging (MRI) as well as its safety. Given that there is no drug currently available on the market for cartilage protection and that research on the efficacy of cartilage protection using MRI is very rare, this study would provide clinically valuable information. In this study, we compared the clinical efficacy of JOINS (200 mg, three times per day) orally administered for one year versus placebo in terms of cartilage protection using MRI. We hypothesized that the JOINS group would show more effective cartilage protection than the placebo group after 1 year of treatment.
Materials and Methods

Patients
We conducted a singlecenter doubleblinded randomized controlled trial at Seoul National University from August 4, 2010 to September 25, 2013 . A minimum of 30 subjects per group was considered necessary for this pilot study. To allow for a 20% dropout rate, we sought to enroll 38 subjects per group. Regard less of gender, patients aged 45-79 years and diagnosed with primary knee OA in the medial tibiofemoral compartment based on the American College Rheumatology Criteria were enrolled in the study. The KellgrenLawrence grade of the knee OA was 2 or 3 with the narrowest point of the medial joint space width at least 2 mm. Exclusion criteria were rheumatoid arthritis or inflammatory arthritis, valgus knee deformity, history of any sur gery on the same knee, secondary knee OA, hypersensitivity to JOINS or acetaminophen, history of venous thromboembolism or high risk of venous thromboembolism, severe renal impair ment with creatinine clearance <30 mL/min (calculated using the CrockroftGault formula), and receipt of intraarticular hyaluro nate injection within months or corticosteroids within 3 months before the screening visit. A computergenerated permuted block randomization table was prepared by the statistician and given to the study's coordinator in a series of sealed envelopes. After study participants provided informed consent, patients were random ized to the JOINS group or the placebo group. After a 2week washout period, patients were administered the investigational drug three times daily for 1 year. The placebo tablet had the same size and shape as JOINS and was manufactured by SK Chemicals. In this study, Tylenol ER 650 mg was provided as the rescue med ication and allowed to be used up to 4,000 mg per day. However, to evaluate symptoms including pain, the subject was requested not to use it within 48 hours before visit to the clinic. The study protocol was approved by the Seoul National University Hospital Institutional Review Board (Protocol No. 0620101140). This study was registered in advance with the Clinical Research Infor mation Service, which is one of the primary registration systems listed on the World Health Organization (WHO) International Clinical Trials Registry Platform (Protocol No. NCT01293955).
MRI and Radiographic Evaluation
The MRI scans were obtained using a 3.0 T MRI unit (Trio TIM; Siemens, Erlangen, Germany) with an 8channel transmit receive knee coil 90 min after intravenous injection of a double dose (0.4 mL/kg) of gadopentetate dimeglumine (Magnevist; Schering AG, Berlin, Germany). For cartilage volume and thick ness measurements, the fatsaturated proton densityweighted threedimensional (3D) sampling perfection with application optimized contrasts using variable flipangle evolution fast spin echo (FSE) sequences were obtained in the same plane using the following parameters: repetition time/echo time (TR/TE), 2,000/50; flip angle, 120°; filed of view (FOV), 136×170; slice thickness, 0.6 mm; and acquisition matrix, 320×256. The volume and thickness of the femoral condyle, medial and lateral tibial plateaus, and patella were measured using a semiautomatic method. First, the segmentation of the radial scan method was used and then the radiology staff performed supplemented image segmentation. T1 maps were generated in a 3 mm thick sagittal slice on each condyle, using a dual flip angle 3D gradientecho sequence with volumetric interpolated breath hold examination using the following parameters: TR/TE, 15.0/4.9 ms; flip angles, 5° and 26°; bandwidth, 199 Hz/pixel; FOV, 140×140 mm; slice thickness, 4.0 mm; number of sections, 20; and matrix, 256×128. Region of interest for the delayed gadoliniumenhanced MRI of cartilage (dGEMRIC) index was examined in the central parts of the medial and lateral femoral condyles and tibial plateaus. In ad dition, sagittal twodimensional proton density and coronal T2 weighted fatsuppressed FSE sequences were acquired to assess the subchondral bone marrow abnormality scores for the entire knee using the WholeOrgan Magnetic Resonance Imaging Score 24) . All MRI analyses were performed by one muscu loskeletal radiologist (CJY). MRI measurements were performed pretreatment and at 1year followup.
Clinical and Safety Evaluation
Clinical scores, including the knee pain visual analog scale (VAS) score and Korean Western Ontario and McMaster Universities Osteoarthritis Index (KWOMAC) were measured pretreatment and at 1 year followup. The safety evaluation of this clinical study was continued for 2 years with regard to the occurrence of adverse events, clinical laboratory tests, vital signs, and electro cardiography.
Statistical Analysis
Differences between the two groups were analyzed with the Stu dent ttest for continuous variables and Pearson chisquare test 
Results
Five patients in the JOINS group and 2 patients in the placebo group were not available for followup at 1year after treatment; thus 33 patients in the JOINS group and 36 patients in the place bo group were analyzed (Fig. 1) . No differences in demographics were observed between the two groups ( Table 1 ).
MRI and Radiographic Results
Changes in the cartilage volume and thickness were not sig nificantly different between groups ( Table 2 ). The change in the dGEMRIC index in the lateral tibial plateau on T1 map ping was higher in the JOINS group than in the placebo group (19.64±114.33 msec vs. -57.77±123.30 msec, p=0.011) (Table 3) . However, other changes were not significantly different between groups. The subarticular bone marrow abnormality scores for the entire knee were not significantly different between groups (Table 4) .
Clinical and Safety Results
VAS and KWOMAC scores were significantly improved in both groups. However, the JOINS group showed significantly greater changes than the placebo group in VAS (-26 Table 5 ). The safety profile was not differ ent between groups (Table 6 ).
Discussion
We analyzed the efficacy of the orally administered JOINS for cartilage protection compared with placebo. The most impor tant findings of this study include that although the changes in cartilage thickness and volume were not different between the two groups, the change in the dGEMRIC index was significantly greater in the lateral tibial plateau in the JOINS group. Therefore, this study shows that JOINS has the potential for superior clinical efficacy compared with placebo in regard to cartilage protection. JOINS is a drug prepared from the ethanol extract of 3 orien tal herbs-Clematis mandshurica, Trichosanthes kirilowii, and Prunella vulgaris that have been widely and traditionally used to decrease pain and improve functional capacity in patients with OA. JOINS is known to have several functions including anti inflammation, immunomodulation, and activation of blood mi crocirculation 2023, 25) . Additionally, several in vitro studies haven shown JOINS has a cartilage protection effect. The first study was performed by Choi et al. 21) using rabbits. In the study, JOINS inhibited proteoglycan degradation in cartilage explant culture, and prophylactic admin istration of JOINS significantly protected the knee joint of rab bits from OAlike changes in a collagenaseinduced OA model. Kim et al. 23 ) also performed a study using rabbit cartilage explant culture and reported that JOINS inhibited matrix degradation by downregulating matrix metalloproteinase (MMP) expres sion and inhibiting MMP activity during the collagen breakdown process. Hartog et al. 22) performed a study using bovine cartilage explants and human peripheral blood mononuclear cells and reported that SKI306X inhibited IL1βinduced proteoglycan re lease and nitric oxide production by cartilage, indicating cartilage protective activity. Recently, Choi et al. 20) performed a study using human OA chondrocytes and cartilage explants and reported that JOINS inhibited IL1βinduced glycosaminoglycan (GAG) release from cartilage explants and inhibited IL1βinduced MMP gene expression. However, all published studies were in vitro, demonstrating the cartilage protection effect of JOINS using chondrocytes from human, bovine, and rabbit articular cartilage.
A clinical study using quantitative MRI has not been previously reported. This study evaluated the effect of JOINS on cartilage protec tion using MRI. Although the changes in cartilage volume and thickness were not different between the treatment and placebo groups, the change of the dGEMRIC index in the lateral tibial plateau was significantly greater in the JOINS group. Considering that knee OA primarily develops in the medial compartment, it is unclear whether the improved dGEMRIC index in the lateral tibial plateau is clinically relevant to the treatment of OA. How ever, Wildi et al. 26) reported similar findings in a study evaluating the efficacy of chondroitin sulfate for cartilage protection using MRI. In the study, the chondroitin treatment group showed sig nificantly less cartilage volume loss in the lateral compartment than the placebo group at 1year followup. Improved cartilage preservation in the lateral compartment may be explained by the fact that, in general, cartilage damage is less severe in the lateral compartment than in the medial compartment; thus, the lateral compartment showed a greater response to cartilage protection agents. Additionally, these agents in the damaged medial com partment might require more time to demonstrate a treatment effect.
In terms of safety, JOINS was equivalent to placebo regarding adverse event occurrence, and this can be considered remarkable given that the most commonly used medications for knee OA are NSAIDs, which cause some welldefined side effects such as gas trointestinal ulcer and hemorrhage and cardiovascular, hepatic, and renal toxicity 811) . There are several limitations of this study. First, the sample size is relatively small owing to the fact that this is a pilot study. Sec ond, interrater reliability could not be tested because only one rater had conducted MRI measurements of all subjects. Third, the 1year followup may be inadequate to detect a cartilage pro tection effect of JOINS using MRI. Although subarticular bone marrow abnormality scores for the entire knee were not different between the two groups at the 1year followup, some patients who agreed to a 2year followup showed changes of the subar ticular bone marrow abnormality scores for the entire knee that were significantly different between groups. In the placebo group, subarticular bone marrow abnormality scores for the entire knee significantly increased, whereas scores were not changed in the JOINS group (Table 7) . A longterm followup may be neces sary to fully elucidate the cartilage protection effect with MRI. Fourth, although the dGEMRIC index was significantly higher in the lateral tibial plateau in the JOINS group, changes in cartilage thickness and volume were not different between the two groups. dGEMRIC is a technique to evaluate cartilage GAG content. Since dGEMRIC can identify GAG loss in early stage of cartilage disease with a higher sensitivity 27) , we think that it is more useful in assessing changes in cartilage than measurement of volume or thickness of cartilage.
Conclusions
The changes in cartilage volume and thickness were not dif ferent between the two groups at 1year followup. However, the change of the dGEMRIC index in the lateral tibial plateau was significantly greater in the JOINS group than in the placebo Fisher exact test. 
